M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 7.35 PLN 0.68% Market Closed
Market Cap: 151.4m PLN

Gross Margin
Molecure SA

51.5%
Current
-99%
Average
48.7%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
51.5%
=
Gross Profit
2.6m
/
Revenue
5.1m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
PL
Molecure SA
WSE:MOC
151.4m PLN
51%
US
Eli Lilly and Co
NYSE:LLY
929B USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
481.1B USD
68%
CH
Roche Holding AG
SIX:ROG
251.1B CHF
74%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
82%
CH
Novartis AG
SIX:NOVN
205B CHF
76%
US
Merck & Co Inc
NYSE:MRK
241B USD
79%
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
82%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
68%
US
Pfizer Inc
NYSE:PFE
144B USD
75%
No Stocks Found

Molecure SA
Glance View

Market Cap
151.4m PLN
Industry
Pharmaceuticals

Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.

MOC Intrinsic Value
4.43 PLN
Overvaluation 40%
Intrinsic Value
Price
M
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
51.5%
=
Gross Profit
2.6m
/
Revenue
5.1m
What is the Gross Margin of Molecure SA?

Based on Molecure SA's most recent financial statements, the company has Gross Margin of 51.5%.

Back to Top